Amyloidosis

Current Opinion in Rheumatology

Volumn 8, Issue 1, 1996, Pages 62-71

  Friman, Claes ^a   Pettersson, Tom ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; AMYLOID A PROTEIN; AMYLOID BETA PROTEIN; AMYLOID P COMPONENT; AMYLOID PRECURSOR PROTEIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; COLCHICINE; CREATININE; CYCLIC AMP; DIMETHYL SULFOXIDE; SERUM AMYLOID A; TERBUTALINE;

AMYLOIDOSIS; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; FAMILIAL MEDITERRANEAN FEVER; HUMAN; KIDNEY AMYLOIDOSIS; KIDNEY TRANSPLANTATION; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOCLAST; OSTEOLYSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCINTIGRAPHY; STEM CELL TRANSPLANTATION; TOPICAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0030033576     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199601000-00012     Document Type: Review

References (69)

1. Husby G: Classification of amyloidosis. Baillieres Clin Rheumatol 1994, 8:503-511. The current classification of amyloidosis is presented along with important definitions and comments on key discoveries in amyloidosis research.
2. Husby G, Araki S, Benditt EP, Benson MD, Cohen AS, Frangione B, Glenner GG, Natvik JB, Westermark P: Nomenclature of amyloid and amyloidosis. Bull World Health Organ 1993, 71:105-108.
3. Nichols WC, Dwulet FE, Liepnieks J, Benson MO: Variant apolipoprotein A1 as a major constituent of a human hereditary amyloid. Biochem Biophys Res Commun 1988, 156:762-768.
4. Maury CPJ, Rossi H: Demonstration of a circulating 65K gelsolin variant specific for familial amyloidosis, Finnish type. Biochem Biophys Res Commun 1993, 191:41-44.
5. Maury CPJ: Biology of disease: molecular pathogenesis of β-amyloidosis in Alzheimer's disease and other cerebral amyloidoses. Lab Invest 1995, 72:4-16. A comprehensive review of the molecular pathogenesis of β-amyloidosis.
6. Glenner GG: Alzheimer's disease: its proteins and genes. Cell 1988, 52:307-308.
7. Yakar S, Livneh A, Kaplan B, Pras M: The molecular basis of reactive amyloidosis. Semin Arthritis Rheum 1995, 24:255-261. A recent and informative review of the molecular basis of reactive amyloidosis.
8. Whitehead AS, De Beer MC, Steel DM, Rits M, Lelias JM, Lane WS, De Beer FC: Identification of novel members of the serum amyloid A protein superfamily as constitutive apolipoproteins of high density lipoprotein. J Biol Chem 1992, 267:3862-3867.
9. Meek RL, Urieli-Shoval S, Benditt EP: Expression of human apoSAA gene in cells of atherosclerotic lesions [abstract]. In VIIth International Symposium on Amyloidosis: Kingston, Ontario, Canada; July 11-15, 1993. Peart River, NY: Parthenon; 1993:44.
10. Marhaug G, Dowton SB: Serum amyloid A: an acute phase apolipoprotein and precursor of AA amyloid. Baillieres Clin Rheumatol 1994, 8:553-573. Current knowledge about SAA is thoroughly presented and discussed.
11. Wilkins J, Gallimore JR, Tennent GA, Hawkins PN, Limburg PC, van Rijswijk MH, Moore EG, Pepys MB: Rapid automated enzyme Immunoassay for serum amyloid. Clin Chem 1994, 40:1284-1290. A rapid automated enzyme immunoassay for SAA is described.
12. Kisilevsky R, Young ID: Pathogenesis of amyloidosis. Baillieres Clin Rheumatol 1994, 8:613-626. The pathogenesis of reactive amyloidosis is presented in a comprehensive and stimulating review.
13. Badolato R, Wang JM, Murphy WJ, Lloyd AR, Michiel DF, Baussermann LL, Kelvin DJ, Oppenheim JJ: Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 1994, 180:203-209. New data describing SAA as a chemoattractant for polymorphonuclear leukocytes and monocytes are presented.
14. Gruys E, Snel FW: Animal models for reactive amyloidosis. Baillieres Clin Rheumatol 1994, 8:599-611. An informative review of experimental amyloidosis.
15. Yakar S, Kaplan B, Livneh A, Martin B, Miura K, Ali-Khan Z, Shtrasburg S, Pras M: Direct evidence for SAA deposition in tissues during murine amyloidogenesis. Scand J Immunol 1994, 40:653-658. Data providing new direct evidence for SAA deposition in tissues during murine amyloidogenesis are presented.
16. Yamada T, Liepnieks JJ, Hluve-Beckmann B, Benson MD: Cathepsin B generates the most common form of amyloid A (76 residues) as a degradation product from serum amyloid A. Scand J Immunol 1995, 41:94-97. Data are presented that indicate that cathepsin B may play an important role in amyloid fibrillogenesis by converting SAA to AA.
17. Meek RL, Benditt EP: Amyloid A gene family expression in different mouse tissues. J Exp Med 1986, 164:2006-2017.
18. Foyn Bruun C, Rygg M, Nordstoga K, Sletten K, Marhaug G: Serum amyloid A protein in mink during endotoxin induced inflammation and amyloidogenesis. Scand J Immunol 1994, 40:337-344. In endotoxin-induced amyloidosis in mink, only SAA2 protein was recovered from hepatic amyloid fibrils.
19. Sörensen U, Andersen O, Holm Nielsen E, Svehag S-E: Native human serum amyloid P component is a single pentamer. Scand J Immunol 1995, 41:263-267. The data presented indicate that native SAP component circulates as a single pentamer, not as a decamer as previously believed.
20. Hamazaki H: Human serum amyloid P component binds to a specific peptide in the presence of calcium. Biochem Biophys Res Commun 1994, 1172-1178. It is shown that human SAP component binds to a carboxylterminal peptide of residues 160-204 of SAP itself in the presence of calcium.
21. Pepys MB, Booth SE, Tennent GA, Butler PJG, Williams DG: Binding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli. Clin Exp Immunol 1994, 97:152-157. Using whole acute phase serum as the protein source and confocal immunofluorescence microscopy, it was shown that C-reactive protein binds to small nuclear ribonucleoproteins, whereas the other pentraxin SAP binds to chromatin and to the nucleolus.
22. Hutchinson WL, Noble GE, Hawkins PN, Pepys MB: The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. J Clin Invest 1994, 94:1390-1396. It is documented that hepatocytes represent the single major site of pentraxin clearance and catabolism in vivo. An important consequence is that SAP bound to tissue amyloid is not degraded locally.
23. Hawkins PN: Diagnosis and monitoring of amyloidosis. Baillieres Clin Rheumatol 1994, 8:635-639. A very comprehensive review of how to diagnose and monitor amyloidosis.
24. Magnus JH, Stenstad T, Husby G: Proteoglycans, glycosaminoglycans and amyloid deposition. Baillieres Clin Rheumatol 1994, 8:575-597. The role of proteoglycans and glycosaminoglycans in amyloidogenesis is expertly reviewed.
25. Simms RW, Prout MN, Cohen AS: The epidemiology of AL and AA amyloidosis. Baillieres Clin Rheumatol 1994, 8:627-634. Existing data on the epidemiology of AL and AA amyloidosis are presented and analyzed.
26. Hazenberg BPC, van Rijswijk MH: Clinical and therapeutic aspects of AA amyloidosis. Baillieres Clin Rheumatol 1994, 8:661-690. An excellent review of the clinical and therapeutic aspects of AA amyloidosis.
27. Okuda Y, Takasugi K, Oyama T, Onuma M, Oyama H: Amyloidosis in rheumatoid arthritis: clinical study of 124 histologically proven cases. Ryumachi 1994, 34:939-946. Findings in 124 histologically proven cases of amyloidosis complicating RA are reported.
28. Woo P: Amyloidosis in children. Baillieres Clin Rheumatol 1994, 8:691-697. Amyloidosis in children is expertly reviewed.
29. Livneh A, Zemer D, Langevitz P, Laor A, Sohar E, Pras M: Colchicine treatment of AA amyloidosis of familial Mediterranean fever. Arthritis Rheum 1994, 37:1804-1811. A retrospective analysis of data abstracted from the charts of 68 familial Mediterranean fever patients with amyloidosis who presented during the period 1974 to 1992 and who were treated with colchicine and followed up for at least 5 years. It was concluded that the therapeutic dosage of colchicine for amyloidosis in familial Mediterranean fever is more than 1.5 mg/d. This dosage was effective only in patients with initial serum creatinine levels of less than 1.5 mg/dL.
30. Helin HJ, Korpela MM, Mustonen JT, Pasternack AI: Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum 1995, 38:242-247. A retrospective study of renal biopsy specimens from 110 patients with RA in whom the clinical renal disease was probably due to RA itself and/or to antirheumatic therapy. It was concluded that the renal morphologic lesion in RA patients with isolated proteinuria and those with hematuria cannot be accurately predicted on the basis of clinical symptoms. Renal biopsy is useful in diagnosis and in assessing therapy and prognosis.
31. Hiki Y, Horii A, Kokubo T, Ishikawa S, Sugiyama T, Shigematsu H, Kobayashi Y: A case of rheumatoid arthritis with renal tubular amyloidosis. Nephron 1994, 68:394-395.
32. Espinosa M, Rodriguez M, Martin-Malo A, Perez R, Moreno E, Gomez JM, Blanco-Molina A. Aljama P: A case of Takayasu's arteritis, nephrotic syndrome, and systemic amyloidosis. Nephrol Dial Transplant 1994, 9:1486-1488.
33. Marenco JL, Sanchez-Burson J, Ruiz Campos J, Jimenez MD, Garcia-Bragado F: Pulmonary amyloidosis and unusual lung involvement in SLE. Clin Rheumatol 1994, 13:525-527.
34. Watts RA, Nicholls A, Scott DG: The arthropathy of the Muckle-Wells syndrome. Br J Rheumatol 1994, 33:1184-1187. Arthropathy in Muckle-Wells syndrome is described in four patients.
35. Kazes I, Deray G Jacobs C: Castleman disease and renal amyloidosis. Ann Intern Med 1995, 122:395-396. A case of Castleman disease and AA amyloidosis is reported. Resection of the lymphomatic mass caused disappearance of the nephrotic syndrome and renal amyloidosis.
36. Maezawa A, Hiromura K, Mitsuhashi H, Tsukada Y, Kanai H, Yano S, Naruse T: Combined treatment with cyclophosphamide and prednisolone can induce remission of nephrotic syndrome in a patient with renal amyloidosis, associated with rheumatoid arthritis. Clin Nephrol 1994, 42:30-32.
37. Makino H, Nagake Y, Murakami K, Hirakawa S, Ota Z: Remission of nephrotic syndrome in a patient with renal amyloidosis associated with Takayasu's arteritis after treatment with dimethylsulphoxide. Ann Rheum Dis 1994, 53:842.
38. Brandwein S, Sipe JD, Cohen AS: Combined treatment with terbutaline and aminophylline inhibits experimental amyloidosis in mice. Arthritis Rheum 1994, 37:1757-1760. A novel pharmacologic approach to the treatment of amyloidosis is presented. Terbutaline and aminophylline, which both elevate cyclic AMP, were shown to inhibit experimental murine AA amyloidosis.
39. Sobn M, Refaie A, Moustafa F, Shokeir A, Hassan N, Sally S, Ghoneim M: Study of live donor kidney transplantation outcome in recipients with renal amyloidosis. Nephrol Dial Transplant 1994, 9:704-708. Results of live donor kidney transplantation in 16 patients with amyloidosis are presented. It is concluded that renal transplantation is a safe procedure in amyloidosis and results are similar to those obtained in patients with glomerulonephritis.
40. Kyle RA, Gertz MA: Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995, 32:45-59. A comprehensive and detailed review covering the clinical aspects of AL amyloidosis.
41. Ozaki S, Abe M, Wolfenbarger D, Weiss DT, Solomon A: Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenström's macroglobulinemia. Clin Immunol Immunopathol 1994, 71:183-189. The subgroup distribution of monoclonal λ chains in the disease states differed markedly from normal. The predominance of the λ VI subgroup among monoclonal λ chains from patients with AL amyloidosis verify previous observations that the λ VI subgroup is particularly amyloidogenic.
42. Miliani A, Bergesio F: AL-amyloidosis in monoclonal gammopathies. Hematologica 1994, 79:364-366.
43. Salvarani C, Gabriel SE, Gertz MA, Bjornsson J, Li CY, Hunder GG: Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 1994, 17:1621-1626. Clinical features of polymyalgia rheumatica and/or giant cell arteritis may be the presenting manifestation of AL amyloidosis, as seen in this report of four patients.
44. Schima W, Amann G, Steiner E, Steurer M, Vormittag W, Steurer M: Sicca syndrome due to primary amyloidosis. Br J Radiol 1994, 67:1023-1025.
45. Tena X, Olivé A, Rivas A, Lorenzo JC, Ariza A, Soler JM: Pseudotumoral articular amyloidosis. Clin Exp Rheumatol 1994, 12:317-320.
46. Derrick EK, Price ML: Primary systemic amyloid with nail dystrophy. J R Soc Med 1995, 88:290-291.
47. Inazumi T, Hakuno M, Yamada H, Tanaka M, Naka W, Tajima S, Harada T, Nishikawa T: Characterization of the amyloid fibril from primary localized cutaneous amyloidosis associated with Sjögren's syndrome. Dermatology 1994, 189:125-128.
48. Calzavara P, da Porto A, Calconi G, Tessarin C, Salandin F: Primary amyloidosis: short-term prognosis is not always unfavorable. Nephron 1994, 67:118-119.
49. Merlini G: Treatment of primary amyloidosis. Semin Hematol 1995, 32:60-79. A careful and detailed review on the chemotherapy and supportive treatment available for patients with AL amyloidosis. The importance of early diagnosis is emphasized.
50. Livneh A, Zemer D, Langevitz P. Shemer J, Soahr E, Pras M: Colchicine in the treatment of AA and AL amyloidosis. Semin Arthritis Rheum 1993, 23:206-214.
51. Gertz MA, Kyle RA: Phase II trial of recombinant interferon alpha-2 in the treatment of primary systemic amyloidosis. Am J Hematol 1993, 44:125-128.
52. Majolino I, Marcenò R, Pecorato G, Scimé R, Vasta S, Liberti G, Rizzo A, Indovina A, Caronia F: High-dose therapy and autologous transplantation in amyloidosis-AL. Hematologica 1993, 78:68-71.
53. van Buren M, Hené RJ, Verdonck LF, Verzijlbergen FJ, Lokhorst HM: Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis. Ann Intern Med 1995, 122:508-510. A new and promising approach to the treatment of AL amylcidosis is presented. Clinical symptoms disappeared and amyloid deposits regressed in a patient with AL amyloidosis treated with syngeneic bone marrow transplantation.
54. Hall R, Hawkins PN, Scott J, Pepys MB, Polak JM, Davies KA: Cardiac transplantation for AL amyloidosis: good quality of life is possible for several years. BMJ 1994, 309:1135-1137. A personal account given by a professor of medicine who had extensive AL amyloidosis and was successfully treated with cardiac transplantation and alkylating chemotherapy.
55. Iwasaki T, Hamano T, Aizawa K, Kobayashi K, Kakishita E: A case of pulmonary amyloidosis associated with multiple myeloma successfully treated with dimethyl sulfoxide. Acta Hematol 1994, 91:91-94.
56. Eriksson S, Janciauskiene S, Merlini G: The putative role of α-1 -antitrypsin in the disaggregation of amyloid λ fibrils. J Intern Med 1995, 237:143-149. α1-Antitrypsin has the ability to disintegrate amyloid λ fibrils in vitro, a finding that may have therapeutic implications in AL amyloidosis.
57. 2M amyloidosis.
58. 2microglobulin amyloid deposits and erosive arthropathy of the wrist and spine in a uraemic patient before hemodialysis. Nephrol Dial Transplant 1995, 10:298-302.
59. 2M amyloidosis.
60. 2M amyloidosis.
61. 2M amyloid, which can be used for diagnostic purposes.
62. 2M amyloid fibrils are almost exclusively macrophages. It is not known whether they are involved in amyloidogenesis or accumulate as a result of amyloid deposition.
63. Sivri A, Celiker R, Sungur C, Gökce Kutsal Y: Carpal tunnel syndrome: a major complication in hemodialysis patients. Scand J Rheumatol 1994, 23:287-290.
64. Goodman TR, McNally E: Shoulder pain in a patient on hemodialysis. Ann Rheum Dis 1994, 53:497-500.
65. Naito M, Ogata K, Shiota E, Oyama M: Amyloid bone cysts of the femoral neck: impending fractures treated by curettage and bone grafting. J Bone Joint Surg Br 1994, 6:922-925.
66. 2M amyloidosis.
67. 2M amyloidosis: a possible approach to quantitate disease activity. Nephrol Dial Transplant 1995, 10:223-229. A detailed study of the kinetics of radiolabeled SAP in hemodialysis patients. SAP clearance was disturbed due to both failing renal elimination and retention in extravascular sties.
68. 2M amyloidosis and in particular with the question of whether the choice of hemodialyzers can exert any beneficial effect on the course of the disease.
69. Naito M, Ogata K, Shiota E, Nakamoto M, Goya T: Hip arthroplasty in hemodialysis patients. J Bone Joint Surg Br 1994, 76:428-431.